BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32945346)

  • 1. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Hosono H; Takei J; Ohishi T; Sano M; Asano T; Sayama Y; Nakamura T; Yanaka M; Kawada M; Harada H; Kaneko MK; Kato Y
    Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
    Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas.
    Kaneko MK; Ohishi T; Takei J; Sano M; Nakamura T; Hosono H; Yanaka M; Asano T; Sayama Y; Harada H; Kawada M; Kato Y
    Oncol Rep; 2020 Dec; 44(6):2517-2526. PubMed ID: 33125138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134-mG
    Tateyama N; Nanamiya R; Ohishi T; Takei J; Nakamura T; Yanaka M; Hosono H; Saito M; Asano T; Tanaka T; Sano M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):177-183. PubMed ID: 34424762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
    Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
    Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Exerted Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor.
    Tanaka T; Ohishi T; Saito M; Suzuki H; Kaneko MK; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):142-149. PubMed ID: 35666554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
    Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A defucosylated anti-PD-L1 monoclonal antibody 13-mG
    Takei J; Ohishi T; Kaneko MK; Harada H; Kawada M; Kato Y
    Biochem Biophys Rep; 2020 Dec; 24():100801. PubMed ID: 32923698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-Epidermal Growth Factor Receptor Antibody (E134Bf).
    Li G; Suzuki H; Takei J; Asano T; Sano M; Tanaka T; Harada H; Mizuno T; Ohishi T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):53-58. PubMed ID: 35471048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry.
    Itai S; Kaneko MK; Fujii Y; Yamada S; Nakamura T; Yanaka M; Saidoh N; Handa S; Chang YW; Suzuki H; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):214-219. PubMed ID: 28891752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors.
    Li G; Ohishi T; Kaneko MK; Takei J; Mizuno T; Kawada M; Saito M; Suzuki H; Kato Y
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.
    Suzuki H; Ohishi T; Asano T; Tanaka T; Saito M; Mizuno T; Yoshikawa T; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.